Company / Capital Expenditures
Harmony Biosciences Holdings, Inc. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$310.0K
FY2025
5-year range
$149.0K / $1.2M
FY2021-FY2025
Trend
-73.1%
vs FY2024
Sector context
#150 of 194
Health Care
What the data says
Harmony Biosciences Holdings, Inc.'s capital expenditures of $310,000 is lower than 77% of companies in the Health Care sector (FY2025).
Based on SEC 10-K filings.
$310,000 in FY2025 with a 5-year CAGR of +15.8%.
Remained stable around $310,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +21.7%
- 5-Year CAGR
- +15.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 194This company $310.0K Sector average $117.5M
▼
-99.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.8%, indicating consistent growth.
- In FY2025, capital expenditures decreased 73.1% year-over-year.
- Ranks #150 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 20.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $310.0K | -73.1% |
| FY2024 | $1.2M | +269.6% |
| FY2023 | $312.0K | +81.4% |
| FY2022 | $172.0K | +15.4% |
| FY2021 | $149.0K | +0.0% |
| FY2020 | $149.0K | +0.0% |
| FY2019 | $149.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026